$PFE Recent News Inversions are not such a sweet deal

New Post Public Reply Private Reply Replies (0) Message Board

Aug 25, 2014 at 11:46 AM

$PFE Recent News

Inversions are not such a sweet deal for fund investors 1:47 p.m. Aug. 18, 2014 - Chuck Jaffe
Tax inversions can be bad for shareholders — and for America 2:31 p.m. Aug. 17, 2014 - Chuck Jaffe
Investors sent on a wild ride by hostile deals 12:56 p.m. Aug. 15, 2014 - David Weidner
Timing this market is guaranteed to make you a loser 1:02 p.m. Aug. 8, 2014 - Mark Hulbert
Tax inversions help, not hurt, the economy 7:20 a.m. Aug. 8, 2014 - Diana Furchtgott-Roth
Mega caps with mega recommendations 7:54 a.m. Aug. 6, 2014 - Mark Hulbert
Zoetis narrows full-year earnings guidance 8:12 a.m. Aug. 5, 2014 - MarketWatch.com
‘Inversion’ payoff for shareholders is muted at tax time 11:42 a.m. Aug. 3, 2014 - Laura Saunders
5 ways to profit from sex (without having it) 8:45 a.m. Aug. 3, 2014 - Charles Passy
AstraZeneca raises earnings view as sales rise 3:01 a.m. July 31, 2014 - MarketWatch.com
Pfizer to buy Baxter’s vaccines for $635 million 8:32 a.m. July 30, 2014 - Anna Prior
U.S. stocks end choppy trade lower 4:16 p.m. July 29, 2014 - Carla Mozee
Herbalife sinks on disappointing results; Darden gains 3:16 p.m. July 29, 2014 - Angela Johnson
Newscast: Investors await Fed meeting 10:01 a.m. July 29, 2014 - MarketWatch
Newscast: Wall Street may gain ground 7:35 a.m. July 29, 2014 - MarketWatch
Pfizer shares rise 1.3% in premarket trade after Q2 results 7:25 a.m. July 29, 2014 - Tomi Kilgore
Pfizer profit rises above estimates 7:24 a.m. July 29, 2014 - MarketWatch.com
The market in a minute: What will GDP mean for the market? 12:47 p.m. July 28, 2014 - The Trading Deck
Correction: Blog points out Valeant's diverse portfolio is key to its success 1:53 p.m. July 21, 2014 - blogs.marketwatch.com
Two rules of thumb for dumping your financial adviser 2:36 p.m. July 18, 2014 - Mark Hulbert

Jackson Hole And Complacency 12:18 a.m. Aug. 24, 2014 - Seeking Alpha
Despite Gains, European Pharma Looks Sickly 1:41 a.m. Aug. 23, 2014 - Barrons.com
Durata exercises milestone payment deferral right 8:02 p.m. Aug. 22, 2014 - Seeking Alpha
Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod - Analyst Blog 5:55 p.m. Aug. 22, 2014 - Zacks.com
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection 3:46 p.m. Aug. 22, 2014 - CNW Group
FDA approves single-pill regimen HIV med 3:32 p.m. Aug. 22, 2014 - Seeking Alpha
Tonix Could Match Pfizer's Biggest Drug's Best Market 9:43 a.m. Aug. 22, 2014 - Seeking Alpha
Pfizer Inc. (PFE): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. Aug. 22, 2014 - Zacks.com
Sweet Lawsuit Home, Alabama 7:35 p.m. Aug. 21, 2014 - The Wall Street Journal Interactive Edition
Astellas-Basilea's Isavuconazole Accepted for EU Review - Analyst Blog 5:30 p.m. Aug. 21, 2014 - Zacks.com
FDA approves Eliquis label expansion 3:51 p.m. Aug. 21, 2014 - Seeking Alpha
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? 3:50 p.m. Aug. 21, 2014 - Seeking Alpha
ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms 2:14 p.m. Aug. 21, 2014 - 247WallSt.com
Contract Researcher Parexel Sees Growth In Biotech 2:00 p.m. Aug. 21, 2014 - Investors Business Daily
Pfizer may make another run at AstraZeneca by year end 11:47 a.m. Aug. 21, 2014 - Seeking Alpha
Illumina Forms Partnerships With Big Pharma Firms 11:03 a.m. Aug. 21, 2014 - Investors Business Daily
Grappling with Inversion-Induced Tax Hits 9:35 a.m. Aug. 21, 2014 - The Wall Street Journal Interactive Edition
Why AstraZeneca (AZN) Stock Is Higher Today 9:35 a.m. Aug. 21, 2014 - TheStreet.com
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog 4:27 p.m. Aug. 20, 2014 - Zacks.com
GlaxoSmithKline: The Bad Isn't All That Bad 3:39 p.m. Aug. 20, 2014 - Seeking Alpha

Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection 9:00 a.m. Today - PR Newswire - PRF
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection 3:46 p.m. Aug. 22, 2014 - PR Newswire - PRF
Palbociclib Expanded Access Program Now Open To Eligible U.S. Patients With HR+, HER2- Advanced Breast Cancer 8:00 a.m. Aug. 21, 2014 - BusinessWire - BZX
Expanding IBD Research Through Collaboration 9:00 a.m. Aug. 20, 2014 - PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana 9:20 a.m. Aug. 19, 2014 - PR Newswire - PRF
Premier Biotechnology & Anti-CTLA4 8:02 a.m. Aug. 18, 2014 - ACCESSWIRE
Pfizer Announces Submission of Palbociclib New Drug Application to the FDA 8:00 a.m. Aug. 18, 2014 - BusinessWire - BZX
Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine 5:01 p.m. Aug. 14, 2014 - BusinessWire - BZX
Advisory Committee on Immunization Practices Votes to Recommend Pfizer’s Prevnar 13® Vaccine in Adults Aged 65 Years and Older 5:43 p.m. Aug. 13, 2014 - BusinessWire - BZX
Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic PeripheralNeuropathy Lyrica® Studies Conducted in China 5:03 p.m. Aug. 12, 2014 - BusinessWire - BZX
Study Links Viagra(R) to Skin Cancer 11:20 a.m. Aug. 12, 2014 - Marketwire
Entia Biosciences' Supplements Could Prevent Dementia 9:55 a.m. Aug. 12, 2014 - ACCESSWIRE
Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics 9:00 a.m. Aug. 12, 2014 - PR Newswire - PRF
23andMe Announces Agreement with Pfizer Inc. to Research Genetics of Ulcerative Colitis and Crohn's Disease 9:00 a.m. Aug. 12, 2014 - PR Newswire - PRF
Renal Pain Global Clinical Trials Review, H2, 2014 4:37 p.m. Aug. 11, 2014 - PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
European Medicines Agency Accepts Application Seeking New Indication For Prevenar 13®1 For Prevention Of Pneumococcal Pneumonia In Adults 8:00 a.m. Aug. 7, 2014 - BusinessWire - BZX
Pain Therapeutics Reports Q2 2014 Financial Results 8:01 a.m. Aug. 5, 2014 - GlobeNewswire
Depomed Announces Appointment of R. Scott Shively as Chief Commercial Officer 4:01 p.m. Aug. 4, 2014 - PR Newswire - PRF
Rascal Flatts Joins the Thousands of People Who Choose Nexium® 24HR Every Day for Their Frequent Heartburn 8:01 a.m. Aug. 4, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AION UT Sets New Safety Standard in Euro NCAP 2026

The New Gold Standard in Safety for Small EVs Hop into your favorite auto forum and you'll hear more than a buzz—it's a full-blown ruckus. The reason? GAC’s AION UT just nabbed a 2026 Euro NCAP Five-Star Safety Rating. Now, this isn’t just another accolade in a crowded trophy room; it’s a statement, a seismic shift in how small electric vehicles stack up in terms...

BYD's Chip Mastery Amid China's Auto Supply Tensions

Chips, the New Battleground in Automotive Innovation Here we are, folks, knee-deep in a tech-driven car revolution where semiconductors aren't just the icing on the cake—they're the cake itself. As vehicles morph into veritable computers on wheels, reliance on chips is hitting a fever pitch. FYI, it's not just about making cars go; we're talking power management,...

MERACH Unveils W60 Plus: A Game Changer for Home Fitness

MERACH's Ambitious Leap into European Markets Walking is one of life's simple pleasures, but it's not always convenient in our work-from-home driven world. That's where MERACH's UltraWalk W60 Plus comes in, dropping anchor in Europe like a brand new ship with all the bells and whistles. What makes this walking pad different, you ask? It's designed to become a natural...

Nuix Leverages AI for Transformative Legal Review

Nuix Unveils AI Innovations in Legal Review Diving headfirst into the evolving world of legal technology, Nuix has just rolled out some serious upgrades to its eDiscovery toolkit. By plucking AI right out of the data science ethers, they're not just dabbling in futuristic tech—they're planting generative AI at the heart of legal review on their SaaS platform, Nuix...

Fosun Pharma Hits the Buyback Button: What's Next?

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

ACG Moves to Acquire Ke?kek for $7.85M Gold Venture

Here's the scoop: ACG Metals Limited is stepping up the game, attempting to snag the Ke?kek gold project in a deal worth up to $7.85 million. This move, they say, is all about bolstering the future of their gold production—and squeezing every ounce out of that Gediktepe facility in Türkiye. It's like squeezing juice from a lemon that's still got a bit of life left....

Hims & Hers Faces Class Action: Investors Beware

Allegations and Legal Pressure There's trouble brewing in the land of health and wellness apps, with Hims & Hers Health, Inc. (NYSE:HIMS) taking center stage. Slap on your glasses, folks, because this one's a doozy. A class-action lawsuit has exploded against the company and some of its officers—allegations flying as they focus on serious accusations of misleading...

53% of European Telecom Users Eye Provider Switch

Change Is Brewing in Europe's Telecom Markets Seems like Europe's telco scene is simmering. Over half of consumers in major European markets are giving their mobile providers the side-eye, ready to jump ship. That's putting the heat on operators who once banked on loyalty programs to keep their customer base intact. Diverse Loyalty Challenges Across Europe What's...

Multiconsult-Rejlers Merger Revs Up Nordic Market Power

A New Powerhouse in the Nordic Consultancy Space September 7, 2026, will likely be etched into the annals of stock market moves, marking the day two titans, Multiconsult and Rejlers, decided to tie the knot. This isn't your average merger. We're talking about a calculated Pan-Nordic push that's been building, and now, well, it's paying off with a potential powerhouse of...

Ping An Climbs Sustainability Ladder, Scores A+ Rating

Sustainability Triumph for Ping An: A+ Upgrade Ping An Insurance (Group) Company of China, Ltd. is having quite the moment, snagging an A+ in the latest 2026 Sustainability Rating from Hang Seng Indexes Company. This ain't just a one-time pat on the back—it's the third year of consecutive improvement. Looks like Ping An's focus on ESG efforts is finally getting the...